Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 107, Issue 6, 2013, Pages 397-404

  Tukahebwa, Edridah M ^a   Vennervald, Birgitte J ^c   Nuwaha, Fred ^b   Kabatereine, Narcis B ^a   Magnussen, Pascal ^c  

^a MINISTRY OF HEALTH   (Uganda)

^b MAKERERE UNIVERSITY   (Uganda)

^c DANISH BILHARZIASIS LABORATORY   (Denmark)

Author keywords

Cure rate; Re infection; Schistosoma mansoni; Uganda

Indexed keywords

ALBENDAZOLE; PRAZIQUANTEL;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GEOMETRIC MEAN INTENSITY; GEOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OCCUPATION; PARASITE IDENTIFICATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SAMPLE SIZE; SCHISTOSOMIASIS MANSONI; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; UGANDA;

CURE RATE; RE-INFECTION; SCHISTOSOMA MANSONI; UGANDA;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTHELMINTICS; CHILD; DRUG ADMINISTRATION SCHEDULE; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRAZIQUANTEL; PREVALENCE; RECURRENCE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; UGANDA; YOUNG ADULT;

EID: 84882967345     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/trt024     Document Type: Article

References (30)

1. Nelson GS. Schistosoma mansoni infection in the West Nile district of Uganda. 1. The incidence of S. mansoni infection. E A Med J 1958;35:311-9.
2. Prentice MA. Distribution, prevalence and transmission of schistosomiasis in Uganda. Uganda Med J 1972;1:136-9.
3. Kabatereine NB, Brooker S, Tukahebwa EM et a.l. Epidemiology and geography of Schistosoma mansoni in Uganda: implications for planning control. Trop Med Int Health 2004;9:372-80.
4. WHO. Helminth Control in School-Age Children: A Guide for Managers of Control Programmes. Geneva: World Health Organization; 2nd ed; 2011.
5. Renganathan E, Cioli D. An international initiative on praziquantel use. Parasitol Today 1998;14:390-1.
6. Stelma FF, Talla A, Sow S et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 1995;53:167-70.
7. Gryseels B, Mbaye A, De Vlas SJ et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 2001;6:864-73.
8. Tchuem Tchuente LA, Southgate VR, Mbaye A et al. Efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, Northern Senegal. Trans R Soc Trop Med Hyg 2001;95:65-6.
9. Danso-Appiah A, De Vlas S. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol 2002;18:125-9.
10. Vennervald BJ, Dunne DW. Morbidity in schistosomiasis: an update. Cur Opin Inf Dis 2004;17:439-47.
11. Frenzel K, Grigull L, Odongo-Aginya E et al. Evidence for a long-term effect of a single dose of praziquantel on S. mansoni-induced hepatosplenic lesions in Northern Uganda. Am J Trop Med Hyg 1999;60:927-31.
12. N'Goran EK, Gnaka HN, Tanner M, Utzinger J. Efficacy and side effects of two praziquantel treatments against Schistosoma haematobium infection among schoolchildren from Côte d'Ivoire. Ann Trop Med Parasitol, 2003;97:37-51.
13. Conlon CP. Schistosomiasis. Medicine33 2005;8:64-7.
14. Fitzsimmons CM, Joseph S, Jones FM et al. Chemotherapy for schistosomiasis in Ugandan fishermen: Treatment can cause arapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E. Inf Immun 2004;72: 4023-30.
15. Colley DG, Secor WE. Immunoregulation and World Health Assembly resolution 54.19: why does treatment control morbidity? Parasitol Int 2004;53:143-50.
16. Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Tropica 2003;86:161-83.
17. Vereecken K, Naus CW, Polman K et al. Associations between specific antibody responses and resistance to re-infection in a Senegalese population recently exposed to Schistosoma mansoni. Trop Med Int Health 2007;12:431-44.
18. Kabatereine NB, Kemijumbi J, Ouma JH et al. Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. Trans R Soc Trop Med Hyg 2003;97:599-603.
19. Kirkwood B. Essentials of Medical Statistics. London: Oxford Blackwell Scientific Publications; 1992.
20. Katz NA, Chaves A, Pellegrino J. A simple device for quantitative stool thick smear technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972;14:397-400.
21. WHO. Prevention, Control of Schistosomiasis Soil-Transmitted Helminthiasis. Geneva: World Health Organization; 2002. Technical Report Series No. 912.
22. Sturrock RF. The Schistosomes and their intermediate hosts. In: Mahmoud AF, Pasvol G, Hoffman SL. Schistosomiasis. London: Imperial College Press; 2001: p. 7-84.
23. Augusto G, Magnussen P, Kristensen TK et al. The influence of transmission season on parasitological cure rates and intensity of infection after praziquantel treatment of Schistosoma haematobiuminfected schoolchildren in Mozambique. Parasitology 2009;136: 1771-9.
24. Picquet M, Vercruysse J, Shaw DJ et al. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg 1998;92:90-3.
25. Brindley PJ, Sher A. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependant on host antibody response. J Immunol 1987;139:215-20.
26. Utzinger J, N'Goran EK, N'Dri A et al. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 2000;5:771-8.
27. Utzinger J, Booth M, N'Goran EK et al. Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of S. mansoni before and after treatment with praziquantel. Parasitology 2001;122:537-44.
28. Sacko M. Assessment of the effect of two different treatment strategies on the morbidity caused by Schistosoma haematobium infections among school aged children in the Niger River Basin, Mali [PhD Thesis]. Copenhagen: University of Copenhagen; 2006.
29. Dunne DW, Butterworth AE, Fulford AJC et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to re-infection. Eur J Immun 1992;22:1483-94.
30. Malenganisho WLM, Magnussen P, Friis H et al. Schistosoma mansoni morbidity among adults in two villages along Lake Victoria shores in Mwanza District, Tanzania. Trans R Soc Trop Med Hyg 2008;102:532-41.